Related Experiment Video
Updated: Jul 1, 2026

08:01
Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
Published on: November 17, 2017
7.7K
Persistent Membrane-Anchored Oligomeric Peptides with Nanopore Formation for Targeted Immune Modulation
Jingtian Cao1, Yao Yu1, Kai Han1
1Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology, School of Chemistry and Chemical Engineering, Tangshan Research Institute, Beijing Institute of Technology, Beijing, 100081, P.R. China.
Angewandte Chemie (International Ed. in English)
|September 11, 2025
Summary
Researchers developed novel helical peptides, TA03, to overcome off-target effects in targeted therapies. TA03 specifically targets PD-L1, forming stable nanopores on tumor cells for enhanced immunotherapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Nanotechnology
Background:
- Off-target effects of recognition molecules are a major challenge in targeted diagnosis and therapy.
- Developing specific molecular structures to minimize these effects is crucial for effective treatment.
Purpose of the Study:
- To design and identify novel oligomeric helical peptides that overcome the challenge of off-target effects.
- To develop a peptide that specifically targets PD-L1 and enhances immunotherapy.
Main Methods:
- Rational design and high-throughput screening of oligomeric helical peptides.
- Amino acid mutations and structural optimizations to identify lead candidates (TA03 and TA10).
- Characterization of TA03's interaction with tumor cell membranes and PD-L1.
Main Results:
- TA03 was identified as a lead candidate specifically recognizing the PD-L1 target.
- TA03 forms stable "hourglass-like" nanopores on tumor cell membranes via aromatic-hydrophobic interactions of tryptophan residues.
- This structure ensures prolonged residence time, persistent PD-L1 interaction, and avoidance of off-target effects.
- TA03 physically disrupts tumor cells, boosting immunotherapy and inhibiting tumor growth.
Conclusions:
- Novel oligomeric helical peptides, exemplified by TA03, can overcome off-target effects for membrane-associated targets.
- TA03's unique structure and PD-L1 targeting offer a promising strategy for enhanced cancer immunotherapy.
- This approach provides a new avenue for designing molecular structures to improve targeted therapies.

